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Abstract During the natural course of chronic hepatitis B
virus infection, immune-tolerant phase is characterized by
high viral replication, the presence of HBV e antigen
(HBeAg), and normal or minimally elevated serum alanine
aminotransferase. Immune-tolerant phase is usually regar-
ded as a benign course of the disease. International
guidelines recommend observation rather than treatment
during immune-tolerant phase. In this article, we review
unresolved issues related to the definition of true immune-
tolerant phase and the benefit of antiviral treatment.
Defining true immune-tolerant phase requires a careful
approach and long-term follow-up. In previous studies,
many patients were misclassified as being immune-tolerant
phase. Noninvasive methods of assessing fibrosis are
warranted for patients in the immune-tolerant phase. Yet,
there has been controversy over the benefit and harm of
antiviral treatment for immune-tolerant phase patients.
Thus, further larger scale studies are needed to investigate
the prognosis of patients in true immune-tolerant phase and
their need for antiviral therapy.
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Abbreviations
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
CHB Chronic hepatitis B




EASL European Association for the Study of the
Liver
ULN Upper limit of normal
AASLD American Association for the Study of Liver
Disease
APASL Asian Pacific Association for the Study of the
Liver
HBsAg Hepatitis B surface antigen
cccDNA Covalently closed circular DNA
qHBSAg Quantitative HBsAg
LSM Liver stiffness measurement
WHO World Health Organization
TDF Tenofovir disoproxil fumarate
Current understanding of immune-tolerant phase
Hepatitis B virus (HBV) infection is one of the most
common liver diseases worldwide. Chronic HBV infection
can progress to cirrhosis or hepatocellular carcinoma
(HCC). In Asia, patients with chronic hepatitis B (CHB)
mostly acquire HBV infection by perinatal transmission or
during infancy [1]. The majority of neonates or children
exposed to HBV develop chronic infection and enter a
prolonged immune-tolerant phase [1].
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In perinatal acquired HBV infection, it usually com-
prises four phases: immune-tolerant phase, immune-clear-
ance or active phase, inactive-carrier phase, and
reactivation phase [2]. The earliest phase is characterized
by very high viral replication, the presence of HBV e
antigen (HBeAg), and normal or minimally elevated serum
alanine aminotransferase (ALT) and/or aspartate amino-
transferase (AST) [3]. This immune-tolerant phase is typ-
ically seen in patients younger than age 30 [4, 5]. The
immune-clearance phase, which occurs during adolescence
or adulthood, is accompanied by continuing hepatitis
activity or episodic hepatitis flares. These might develop to
fibrosis or cirrhosis during the HBeAg-positive phase or
result in declining serum HBV DNA and HBeAg sero-
conversion. After HBeAg seroconversion, most patients
enter the ‘inactive’ phase, which is characterized by sus-
tained normal serum ALT and low HBV DNA [6]. How-
ever, hepatitis may relapse because of reactivation of HBV
with either HBeAg seroreversion or development of pre-
core or basal core prompter mutations. The
immunopathogenesis of HBeAg-negative hepatitis is sim-
ilar to that of HBeAg-positive hepatitis. Therefore, this
phase is considered a variant of immune-clearance phase
[7].
HBeAg is a small immunogenic secretory viral protein.
HBeAg can pass through the placenta and induce clonal
deletion of T cells against HBV in the fetus [8]. When the
infection is acquired at birth, viral replication is usually
very high, but hepatic damage is minimal. Liver biopsy
typically shows no fibrosis and minimal inflammation. This
can be explained by the relative lack of immune pressure
on the virus [9]. Early natural history studies of immune-
tolerant phase revealed a benign disease course. A study
using paired liver biopsy data showed minimal progression
of liver injury over 5 years among patients who remained
in the immune-tolerant phase [10]. Three (6.3%, 3/48)
patients had fibrosis progression and four (12.1%, 4/33)
patients of F1 at baseline regressed to F0. Thus, interna-
tional guidelines recommend observation rather than active
treatment for patients in the immune-tolerant phase
[4, 5, 11].
Challenges on definition of immune-tolerant phase
‘‘Defining true immune-tolerant’’ phase is challenging.
Both natural killer (NK) and T cells are functionally
impaired in the immune-tolerant and immune-active phases
[12]. In one study, the proportion of NK cells in the liver
was significantly higher in patients in the immune-tolerant
phase compared to those in the immune-clearance phase
[13]. In addition, there might be intrahepatic HBV-specific
T cell activities in immune-tolerant-phase patients, even in
the absence of liver inflammation [14]. A histology study in
India showed that approximately 40% of HBeAg-positive
patients with persistently normal ALT had necro-inflam-
mation and fibrosis histologic fibrosis C stage 2 [15]. In a
retrospective cohort study in Korea, it was shown that the
risk of developing hepatocellular carcinoma (HCC) was
higher in untreated patients in the immune-tolerant phase
than patients in the immune-active phase on antivirals
(12.7% vs. 6.0%, p = 0.001) [16]. One possible reason for
the poor outcome of immune-tolerant patients in previous
studies is misclassification of patients in immune clearance
phase as immune-tolerant. For example, in the Korean
study, the mean age of the immune-tolerant patients was
38 years and 26% of immune-tolerant patients had HBV
DNA 4–7 log IU/ml, which were atypical features for
immune-tolerant phase [16]. In the Indian histology cohort,
the lower range HBV DNA among HBeAg-positive
patients with persistently normal ALT was only 2.78 log
copies/ml, which was too low for immune-tolerant phase
[15]. Therefore, defining immune-tolerant phase is chal-
lenging, and whether a true immune-tolerant phase exists is
debatable. The 2017 European Association for the Study of
the Liver (EASL) Clinical Practice Guidelines renamed
this phase as HBeAg-positive chronic HBV infection
instead of immune-tolerant phase to avoid confusion in
terminology [11].
Refining the definition of immune-tolerant using
biomarkers
Normal ALT level
Normal ALT is a key criterion to define immune-tolerant
phase. The upper limit of normal (ULN) ALT in healthy
subjects is 29–33 U/l for males and 19–25 U/L for females
[17–19]. The American Association for the Study of Liver
Diseases (AASLD) defines normal ALT as\ 30 U/l for
males and\ 25 U/l for females [5] (Fig. 1). The Asian
Pacific Association for the Study of the Liver (APASL) and
EASL guidelines use the established ALT cutoff of 40 U/L
[4, 11]. In the definition of normal ALT, metabolic risk
factors for fatty liver disease are generally excluded. Hence
a CHB patient in immune-tolerant phase can have elevated
ALT if there is co-existing fatty liver disease, which has a
prevalence of approximately 29.6% in Asia [20].
On the other hand, some patients with normal ALT can
have liver fibrosis, as immune clearance activities might be
intermittent and quiet down when ALT is checked. In a
prospective study, 10% of HBeAg-positive patients with
normal ALT had advanced fibrosis as assessed by transient
elastography [21]. The risk for advanced liver fibrosis
increases in HBeAg-positive patients older than 35 years
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with ALT greater than 0.5 times the ULN. Therefore,
normal ALT alone in HBeAg-positive patients is insuffi-
cient to define immune-tolerant in CHB.
HBV DNA levels
HBV DNA is expected to be very high in patients who
have not experienced any immune clearance. In HBeAg-
positive asymptomatic children, HBV DNA is in gen-
eral[ 7 log IU/ml [22] [Fig. 1]. The EASL Clinical
Practice Guidelines has adopted HBV DNA[ 7 log U/ml
to define HBeAg-positive chronic infection [11]. AASLD
guideline sets a lower bar of HBV DNA[ 1 million IU/ml
to define immune-tolerant phase, which has a risk of mis-
classifying some patients in immune-clearance phase as
immune-tolerant [23]. Hence one should have a high
degree of suspicion that a HBeAg-positive patient with
normal ALT is not in true immune-tolerant phase but has
stepped into immune clearance when HBV DNA is\ 7
log IU/ml.
Fig. 1 Guidelines for patients with immune tolerant chronic hepatitis B infection
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HBsAg level
Quantification of hepatitis B surface antigen (HBsAg)
largely reflects the concentration of covalently closed cir-
cular DNA (cccDNA) in the liver in HBeAg-positive
patients [24]. HBsAg is translated from mRNA of the
transcriptional active template cccDNA, which reflects the
number of infected hepatocytes [25]. The mean baseline
HBsAg levels differ significantly during different phases of
CHB [26]. The HBsAg level is highest in immune-tolerant
phase and lowest in liver cirrhosis phase: immune-tolerant
(4.53 - 4.96 log10 U/mL), immune-clearance
(4.03 - 4.37 log10 IU/mL), e antigen negative hepatitis
(2.95 log10 IU/mL), low replicative (3.18 log10 IU/mL),
and liver cirrhosis (2.69 log10 IU/mL) [26–28]. In one
longitudinal cohort study in Hong Kong, HBsAg remained
persistently high at approximately 5 log IU/mL in patients
of immune-tolerant phase over a period of 8 years [29].
Thus, high HBsAg level may assist differentiation of
immune-tolerant from immune-clearance in HBeAg-posi-
tive patients [30]. However, no clear HBsAg cutoff value
has been identified with high sensitivity and specificity to
define immune-tolerant phase.
Liver biopsy and non-invasive assessment: impact
of age
When the clinician is not certain if a HBeAg-positive
patient is in the immune-tolerant phase, liver biopsy can be
performed to detect evidence of necro-inflammation or
liver fibrosis, which will trigger commencement of
antiviral therapy (Fig. 1). According to the AASLD
guideline, liver biopsy should be considered for patients
with persistent borderline normal or slightly elevated ALT,
in particular those 40 years or older and infected at a young
age [31]. The APASL guideline states that liver biopsy
should be considered for patients with abnormal transient
elastography and older than age 35. The EASL guideline
recommends that patients with ALT 41–80 IU/L be eval-
uated by transient elastography and/or liver biopsy, while
antiviral therapy should be considered for patients older
than age 30 even without assessment of liver fibrosis.
While older age is generally agreed to be a good surrogate
of immune-clearance, the cut-off age for immune-tolerant
phase is unclear.
As reflected in the guidelines, liver biopsy is invasive
and cannot be performed in all cases. There is an increasing
need for noninvasive assessments such as transient elas-
tography and/or serum tests. Noninvasive tests might be
used to assess for the severity of fibrosis [32, 33]. Patients
who have liver stiffness measurement[ 8 kPa by transient
elastography or APRI[ 1.5 might have significant fibrosis.
However, clinical application of noninvasive markers has
several limitations. The diagnostic accuracy of noninvasive
test is sometimes unsatisfactory. For example, AST/platelet
ratio index showed moderate diagnostic performance for
the assessment of fibrosis in patients with CHB [34].
Although liver stiffness measurement may have a higher
diagnostic accuracy than serum noninvasive tests [35, 36],
its usefulness may be reduced in obese patients [37]. In
general, the specificity of liver stiffness measurement to
exclude significant fibrosis in patients with normal ALT is
very high [38]. Sequential use of liver stiffness measure-
ment and serum indexes such as Forn’s index or Enhanced
Liver Fibrosis test improve the accuracy to predict liver
fibrosis [39, 40].
Controversies of antiviral treatment in immune-
tolerant patients
The need to treat
There has been controversy over the need to treat patients in
immune-tolerant phase. It is apparent that some patients will
undergo spontaneous HBeAg seroconversion and may not
need antiviral therapy. Patients with spontaneous HBeAg
seroconversion before age 30 have an excellent prognosis; the
15-year cumulative incidence of cirrhosis and HCCwas 3.7%
and 2.1%, respectively [41]. On the other hand, older patients
who remain in HBeAg-positive state may have poorer out-
come, and some patients might silently move into immune
clearance phase with liver injury. In oneKorean study, among
patients with a high viral load and normal or slightly elevated
serum ALT for at least 12 months, 60% had significant
fibrosis and 62% showed significant histology [42]. In Hong
Kong, amongHBeAg-positive patients older than age 35with
ALT greater than 0.5 9 the ULN, 37% had advanced fibrosis
as assessed by transient elastography [21].
The public health burden of HBV is increased by its
lifelong course and the requirement for long-term follow-
up [43]. There is a risk of horizontal HBV transmission
from immune-tolerant patients with very high viral load.
Another issue is vertical transmission of HBV by high viral
load mothers. Even with hepatitis B immunoglobulin,
timely birth dose and 3-dose vaccination to the newborn,
approximately 5–10% of newborns will acquire HBV
infection if maternal viral load is higher than 6 log IU/ml
[44, 45]. Therefore, international guidelines recommend
that HBeAg-positive mothers with HBV DNA[ 6 log IU/
mL or 200,000 IU/mL should receive oral antivirals during
the last trimester, together with hepatitis B immunoglob-
ulin and vaccination for newborns.
Most children and adults will progress from the
immune-tolerant phase to the immune-active phase. There
is controversy whether the risk of HCC will increase in
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immune-tolerant patients if they are not treated. One
Korean study showed that the 10-year cumulative inci-
dence of HCC was 12.7% among patients in the immune-
tolerant phase compared to 6.0% among those in the
immune-active phase, though there is concern on possible
misclassification of immune-tolerant patients in this study
[16]. Another Koreans study showed the contrary; the
cumulative risk for HCC was similar in patients in the
immune-tolerant phase and those with a virologic response
groups to antivirals (1.1% and 2.7% vs. 1.0% and 2.9% at 5
and 10 years, respectively; p = 0.704) [46]. A study
reported that suppressing HBV DNA to prevent HCC and
cirrhosis is cost-effective in immune-tolerant phase
patients [47]. The low cost of antiviral drugs nowadays has
lowered the financial barrier for universal coverage of
HBV treatment in most countries.
Limitations of antiviral therapy
Patients in immune-tolerant phase are very difficult to treat.
Patients in immune-tolerant phase respond poorly to inter-
feron-alpha therapy [48]. In a recent study using 8 weeks of
entecavir followed by combination peginterferon and ente-
cavir therapy for 40 weeks in adults in the immune-tolerant
phase, only 4% patients had HBeAg seroconversion and 0%
patients had HBV DNA\ 1000 IU/ml at 48 weeks after
completion of peginterferon treatment [49]. A randomized
controlled trial of tenofovir disoproxil fumarate (TDF) versus
emtricitabine and TDF in HBeAg-positive patients with high
HBV DNA ([ 7 log IU/mL) and normal ALT showed that
HBV DNA can be suppressed in\ 60% patients and HBeAg
seroconversion developed in\ 5% patients in 4 years [49].
After the cessation of TDF-based treatment, all patients
experienced HBV DNA relapse to[ 2000 IU/mL within
4 weeks, and 50% showed an increase in ALT [50]. As a
result, long-term treatment is expected if nucleot(s)ide ana-
logue is used in immune-tolerant patients, and adherence to
treatment among young patients will be a concern. Consid-
ering the minimal risk for disease progression, anticipated
long-term treatment in younger patients, poor response to
treatment in patients in the immune-tolerant phase, lack of
data on improvement in long-term outcomes, nucleot(s)ide
analogue therapy is generally not recommended for patients in
immune-tolerant phase of CHB at the present moment [51].
Summary, recommendations, directions for future
research
No international consensus has been made to define true
immune-tolerant phase and studies on prognosis and
treatment response in true immune-tolerant phase are
limited. There is no placebo-controlled study on the long-
term benefit of antiviral therapy in immune-tolerant phase
over observation. Given the low event rate of HCC and
requirement of long-term follow-up, a randomized, con-
trolled study to evaluate the benefit of antiviral treatment in
immune-tolerant patients seems not very feasible. Most
clinicians agree on the need to identify advanced fibrosis
and appropriate treatment in HBeAg-positive patients with
a high viral load and a normal ALT level for older patients,
but the cut-off age for detailed assessment is debatable. In a
true immune-tolerant phase, the risk for disease progres-
sion is minimal. Even after antiviral treatment is started,
the virological response is unsatisfactory and off-treatment
relapse often occurs. Thus, further studies are needed to
determine the assessment and treatment strategy for
immune-tolerant patients.
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